Post-ASH report https://service.datamonitorhealthcare.com/hkc/thought-leadership/article244408.ece
AML disease analysis report https://service.datamonitorhealthcare.com/hkc/disease/oncology/leukemia/acute-myeloid-leukemia/disease-analysis/article214159.ece
Multiple myeloma disease analysis report https://service.datamonitorhealthcare.com/hkc/disease/oncology/other-hematological-cancers/multiple-myeloma/disease-analysis/article219424.ece
CLL disease analysis report  https://service.datamonitorhealthcare.com/hkc/disease/oncology/leukemia/chronic-lymphocytic-leukemia/disease-analysis/article222425.ece

Other platforms in addition to SoundCloud:
Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz
TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/
Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

Post - ASH Podcast

Nitin Jain, MD, associate professor in the department of leukemia, University of Texas MD Anderson Cancer Center, is the guest of honor to provide a comprehensive and simplified overview of the major advances in chronic lymphocytic leukemia over the past two decades. Dr. Jain talks mutations and time to treatment, prognostic markers, BTK inhibitors, combination regimens, current research, toxicities, cost, and a host of controversies with trial comparator arms, drug similarities, and MRD.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

All Things CLL With Nitin Jain

Wir berichten vom Europäischen Hämatologiekongress, EHA. In Frankfurt haben wir u.a. mit Dr. Kai Rejeski von der LMU München gesprochen über aktuelle Empfehlungen der EHA und EBMT für „Immune effector cell-associated hematotoxicity“ (ICAHT), also hämatologische Nebenwirkungen, die unter CAR-T-Zell-Therapie auftreten. Zudem gibt es aktuelle Daten zum Sechs-Jahres-Update der CLL14-Studie mit Venetoclax /Obinutuzumab bei chronischer lymphatischer Leukämie von Dr. Othman Al-Sawaf, Uniklinik Köln. 

Weitere Themen der Folge: Wie das Mikrobiom die Wirksamkeit von Therapien beeinflussen kann und welche Rolle dabei eine Antibiose spielt. Zudem diskutieren wir, welche neuen Optionen für das transfusionsabhängige Myelodysplastische Syndrom (MDS) mit niedrigem Risiko in der Pipeline stehen. So könnte bald in der Erstlinie Luspatercept und in der Zweitlinie Imetelstat zugelassen werden. Denn bei einigen Patient:innen führen sie zu anhaltender Transfusionsfreiheit.

Komplette Berichterstattung vom EHA:
www.medical-tribune.de/eha-2023

Publikation zu ICAHT:
https://ashpublications.org/blood/article/doi/10.1182/blood.2023020578/496185/Immune-Effector-Cell-Associated-Hematotoxicity
 
Abstract CLL14-Studie:
https://library.ehaweb.org/eha/2022/eha2022-congress/357012/othman.al-sawaf.venetoclax-obinutuzumab.for.previously.untreated.chronic.html

O-Ton Onkologie

Kongress-Special: EHA2023

By Myself - Dev Ft Valious

ANOTHER QUICK EDIT I MADE IN AN HOUR

BEEN ON A CREATIVE STREAK! ENJOY AND VIBE!

FREE DL!

I LOVE KASKADE!!!! 
I LOVE STROBELITE SEDUCTION!
LETS GOOO!

KASKADE - ONE HEART (HEALBOI BEDSIDE EDIT) (FREE DL!)

At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of health among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). In this interview, he further discusses how the treatment landscape of CLL/SLL has changed with the introduction of BTK inhibitors and his next steps for this research.

Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD

Chadi sits down with Dr. Matt Davids, Director of Clinical Research in the Division of Lymphoma at Dana-Farber Cancer Institute, to unpack the latest breakthroughs in leukemia and chronic lymphocytic leukemia (CLL) from the ASH annual meeting. A pioneer in CLL treatment, Dr. Davids recounts the development of venetoclax, a transformative therapy he helped bring to clinical use over a decade ago, setting the stage for discussions on emerging updates. Together, they explore advancements in BTK inhibitors across three distinct classes, the potential of novel targeted therapies, innovative combination regimens, and the shifting paradigms in treating blood cancers, including a nod to the latest clinical trials of high potential.
 
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

CLL Updates and the Venetoclax Story With Matt Davids

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Doing this for fun
hmu if you wanna work 
discord: devsonic123

In O-Ton Onkologie wird alles diskutiert, was mit Krebs zu tun hat – mit dem Fokus darauf, was für Medizinerinnen und Mediziner relevant ist: Wir berichten von Neuigkeiten zur Diagnostik und Therapie, stellen Wissenschaflterler:innen vor oder diskutieren praxisrelevante News von ausgewählten Kongressen. Der Podcast ist ein Projekt von Journal Onkologie und Medical Tribune Onkologie/Hämatologie aus der MedTriX Group. Wir sprechen alle 14 Tage mit Expert:innen aus der Onkologie und Hämatologie.

Das Team Onkologie sind Antje Blum, Chefredakteurin des Journal Onkologie, und ihre Stellvertreterin, Dr. Astrid Heinl, die beiden Chefredakteurinnen der Medical Tribune Onkologie/Hämatologie, Elisa Breuer und Dr. Judith Besseling sowie Jochen Schlabing, Teamleiter Onkologie in der MedTriX Group.

Den Podcast O-Ton Onkologie gibt es jeden zweiten Mittwoch auf den gängigen Podcast-Plattformen. Abonnieren Sie uns und machen Sie auch gerne Themenvorschläge. Kontakt zur Redaktion unter: o-ton-onkologie@medtrix.group

Mehr unter:
www.medical-tribune.de/o-ton-onkologie
www.journalonko.de/podcasts/liste

• MedTriX Group auf LinkedIn: www.linkedin.com/company/medtrix-group/
• Medical Tribune Deutschland auf LinkedIn: www.linkedin.com/showcase/medical-tribune-de/

HUSBAND | TIO | FRIEND 🖤 
1/2 OF THE BAND LOTUS CLOUD

Healthcare Unfiltered is an honest, raw, timely podcast tackling any and all topics in healthcare that affect stakeholders. Dr. Chadi Nabhan uses his dynamic conversational skills to challenge his guests to address controversial and important topics. He also brings on world renowned experts to discuss clinical advances in medicine.

New tracks tagged #CLL